Clinical Trials Detalhe
Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology
Visão Geral
Gender
ALL
Idade
from 50 Years to 99 Years
Fase
N/D
Tipo de Estudo
OBSERVATIONAL
Localização
Centro Hospitalar e Universitario de Coimbra (Coimbra, Portugal)
Centro Hospitalar de Lisboa Central, E.P.E. (Lisbon, Portugal)
Clinicaltrial.gov
https://classic.clinicaltrials.gov/ct2/show/NCT03842163Sumário
The main purpose of this study is to determine the prevalence of ATTR Cardiomyopathy among patients admitted due to Left Ventricular Hypertrophy (LVH) \>15mm of unknown etiology by using a 99mTc-tracer scintigraphy based protocol
Condições
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Elegibilidade
Inclusion criteria: * Patient signed inform consent. * Males and Females. * Age ≥50 years. * Left ventricular hypertrophy (LVH) defined as end-diastolic LV maximum wall thickness (MWT) ≥15mm in Echocardiogram. * Plan to undergo or recently underwent radionuclide bone scintigraphy and/or SPECT with any of the following radio labelled tracers: 99mTc-DPD or 99mTc-PYP or 99mTc-HMDP. Exclusion criteria: * Etiological diagnosis explaining the LVH (p.e. Sarcomeric HCM, Myeloma, Fabry disease, Sarcoidosis, Any type of amyloidosis (AA, AL, TTR) * Severe aortic stenosis defined as aortic valve area (AVA) \< 1.0 cm2